14. Wood L, et al.: In: Society for Immunotherapy of Cancer (SITC): November 8, 2019 2019; National Harbor, MD . 15. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J: Antibody -Dependent Cellular Cytotoxicity Activity of a Novel Anti- PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells . Cancer Immunol Res 2015, 3(10):1148-1157. 16. Heery CR, O'Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, Lamping E, Oyelakin I, Marte JL, Lepone LM et al : Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial . Lancet Oncol 2017, 18(5):587-598. 17. Donahue RN, Lepone LM, Grenga I, Jochems C, Fantini M, Madan RA, Heery CR, Gulley JL, Schlom J: Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti- PD-L1 monoclonal antibody. J Immunother Cancer 2017, 5:20.